229. Autoimmune pulmonary alveolar proteinosis Clinical trials / Disease details

Clinical trials : 43 / Drugs : 34 - (DrugBank : 8) / Drug target genes : 3 - Drug target pathways : 14

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03316651 (ClinicalTrials.gov)	August 2016	27/8/2017	Sequential Therapy With WLL/Inhaling GM-CSF for Autoimmune Pulmonary Alveolar Proteinosis	A Multicenter Clinical Study of the Sequential Therapy With Whole Lung Lavage/Inhaling Granulocyte-macrophage Colony Stimulating Factor in Adult Patients With Severe Autoimmune Pulmonary Alveolar Proteinosis in China	Pulmonary Alveolar Proteinosis;Treatment	Drug: GM-CSF	Dai Huaping	NULL	Recruiting	18 Years	N/A	All	60	Phase 2	China
2	NCT01983657 (ClinicalTrials.gov)	January 2012	7/11/2013	Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.	Study of Subcutaneous Injection of Low-dose Recombinant Granulocyte Macrophage-Colony Stimulating Factor (rhGM-CSF) +/- Whole Lung Lavage(WLL) in Pulmonary Alveolar Proteinosis.	Pulmonary Alveolar Proteinosis	Drug: rhGM-CSF;Procedure: Whole Lung Lavage(WLL)	Shanghai Pulmonary Hospital, Shanghai, China	NULL	Recruiting	17 Years	80 Years	Both	40	Phase 2	China
3	NCT00901511 (ClinicalTrials.gov)	July 2009	11/5/2009	Whole Lung Lavage (WLL)/Inhaled Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (PAP)	Whole Lung Lavage Followed by Inhaled Sargramostim in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis	Pulmonary Alveolar Proteinosis	Drug: GM-CSF [Leukine (Sargramostim)];Procedure: WLL	IRCCS Policlinico S. Matteo	Agenzia Italiana del Farmaco	Enrolling by invitation	18 Years	N/A	Both	18	Phase 2/Phase 3	Italy
4	EUCTR2008-007086-23-IT (EUCTR)	12/12/2008	27/01/2009	Whole lung lavage followed by inhaled Sargramostim in the treatment of autoimmune pulmonary alveolar proteinosis. - WLL/inhaled GM-CSF in autoimmune PAP	Whole lung lavage followed by inhaled Sargramostim in the treatment of autoimmune pulmonary alveolar proteinosis. - WLL/inhaled GM-CSF in autoimmune PAP	Autoimmune PAP MedDRA version: 9.1;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis	Trade Name: Leukine INN or Proposed INN: Sargramostim	OSPEDALE POLICLINICO S. MATTEO	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy